Clinical Trial Finds Yoga Eases Anxiety, Fatigue and Insomnia in 410 Cancer Survivors
Updated
Updated · The Guardian · Jun 1
Clinical Trial Finds Yoga Eases Anxiety, Fatigue and Insomnia in 410 Cancer Survivors
2 articles · Updated · The Guardian · Jun 1
A 410-patient U.S. randomized trial found gentle hatha and restorative yoga meaningfully reduced overall mood disturbance, anxiety, fatigue and insomnia in cancer survivors compared with standard care alone.
The four-week YOCAS program paired standard survivorship care with two 75-minute instructor-led classes and at least 30 minutes of weekly home practice using 18 poses, breathing exercises and mindfulness.
Researchers said the intervention addresses a major gap because up to 95% of survivors experience sleep problems and more than half report mood disturbance, anxiety or fatigue during or after treatment.
Presented at ASCO in Chicago, the study involved survivors with non-metastatic cancer—average age 54—and three in four had breast cancer, suggesting a non-drug option for patients already managing multiple medications.
Could digital yoga programs deliver the same powerful mental health benefits to cancer survivors as in-person classes?
With yoga's benefits now proven, what's stopping it from becoming a standard, insured part of cancer care?
ASCO 2026: YOCAS Phase III Trial Shows Gentle Yoga Significantly Improves Sleep and Mental Health in Cancer Survivors
Overview
The Yoga for Cancer Survivors (YOCAS) study, presented at the 2026 ASCO Annual Meeting, is a major phase III trial showing that structured yoga can significantly improve the lives of cancer survivors. By engaging in gentle Hatha yoga, participants experienced relief from mood swings, anxiety, and fatigue, as well as better sleep quality and decreased insomnia. These benefits address a cluster of persistent symptoms that often occur together and can greatly reduce well-being after cancer treatment. The YOCAS trial marks an important advance, offering a non-pharmacological solution for survivors facing ongoing challenges.